Is Ascendis Pharma A/S a good investment? Ascendis Pharma A/S (ASND) is currently trading at 275.39 USD. Market analysts have a consensus price target of 308.32 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 17.53. This valuation is generally in line with the broader market.
Earnings Schedule: Ascendis Pharma A/S is expected to release its next earnings report on Feb. 10, 2027. The market consensus estimate for Forward EPS is 12.04.
No, it does not currently pay a dividend.
Ascendis Pharma A/S is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Feb. 10, 2027. The company currently has a trailing EPS of 15.71.
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Community Discussion